Scancell (LON:SCLP) Hits New 52-Week High - Here's What Happened

Key Points

• 52-week high: Scancell's stock hit a new 52-week high on Tuesday, trading as high as GBX 16.50 and last at GBX 16.25 on volume of 4,783,882 shares, up from a prior close of GBX 15.10.
• Financial profile: The company has a market cap of £168.64 million, a negative debt-to-equity of -193.29, a high quick ratio (13.01) but a low current ratio (0.56), and a trailing P/E of -29.55; its 50- and 200-day moving averages are GBX 12.59 and GBX 11.47 respectively.
• Pipeline progress: Scancell is a clinical-stage biotech using Immunobody® and Moditope® platforms, with lead asset iSCIB1+ showing monotherapy activity in adjuvant melanoma and added benefit versus checkpoint inhibitors in the ongoing Phase 2 SCOPE trial in advanced melanoma.

Scancell Holdings plc (LON:SCLP - )'s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as GBX 16.50 and last traded at GBX 16.25, with a volume of 4783882 shares changing hands. The stock had previously closed at GBX 15.10.

Scancell Price Performance

The company has a debt-to-equity ratio of -193.29, a quick ratio of 13.01 and a current ratio of 0.56. The company's 50 day moving average price is GBX 12.59 and its 200 day moving average price is GBX 11.47. The company has a market cap of £168.64 million, a price-to-earnings ratio of -29.55 and a beta of 0.45.

About Scancell

Scancell LSE: SCLP is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.